Aprindine


Concise Prescribing Info
Indications/Uses
Supraventricular and ventricular arrhythmias.
Dosage/Direction for Use
Adult : PO Initial: 150-200 mg/day in divided doses. Maintenance: 50-100 mg/day.
Dosage Details
Oral
Supraventricular arrhythmias, Ventricular arrhythmias
Adult: Initially, 150-200 mg daily in divided doses, up to 300 mg/day may be used under strict observation for the 1st 2-3 days if needed. Usual maintenance: 50-100 mg daily.
Contraindications
Advanced heart failure, severe conduction disturbances, parkinsonism, convulsive disorders.
Special Precautions
Bradycardia, hypotension, hepatic or renal impairment. Perform blood and LFT during therapy.
Adverse Reactions
Tremor, vertigo, ataxia, diplopia, memory impairment, hallucinations, convulsions; nausea, vomiting, bloating, hepatitis, cholestatic jaundice.
Potentially Fatal: Agranulocytosis.
Drug Interactions
Amiodarone.
Action
Description: Aprindine is a class Ib antiarrhythmic agent which directly interferes with depolarisation of the cell membrane by blocking the fast inward current of Na into cardiac cells. It has a limited effect on the rate of change of the depolarisation phase of the action potential, shortens the repolarisation phase and the QT interval and elevates the fibrillation threshold.
Pharmacokinetics:
Absorption: Readily absorbed from the GI tract.
Distribution: 85-95% bound to plasma proteins.
Excretion: Excreted in the urine and bile. Half-life: about 20-27 hr.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Aprindine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in